Evaluation of the Cost-Effectiveness of Vaccination of Children with 5-valent Vaccine against Rotavirus Infection in the Russian Federation

This article is devoted to the issue of rotavirus infection in pediatric population and demonstrates worldwide prevalence of rotavirus among the causes of viral gastroenteritis and its persistent leadership among the causes of fatal diarrhea in children of the first 5 years of life. Specific prevention of rotavirus infection has been actively carried out around the world since 2005. Nowadays, we have adequate experience in the use of various rotavirus vaccines bolstered by their implementation in immunisation schedules for infants. The authors provide data on the efficacy and safety of rotavirus vaccines licensed and used in Russian Federation, involving the results of studies on safety, immunological and clinical efficacy of one of the pentavalent rotavirus vaccines.

show abstract

New Possibilities of Preventive Immunization for Rotavirus Infection in Russian Federation. Overview of the Innovative Rotavirus Vaccine Profile

Namazova-Baranova

Федосеенко

Калюжная

et al. 2023

Pediatr. farmakol.

View full text Add to dashboard Cite

show abstract

Rotavirus infection. the possibilities of timely vaccination

et al. 2018

View full text Add to dashboard Cite

The incidence of acute intestinal infections in Russia is ranked 3rd 4th among all infectious diseases, and rotavirus is the most frequent etiologic factor in children under 5 years old. Almost 40% of children under the age of two have three episodes of rotavirus infection, the same group undergo the most severe course of the disease. Rotavirus gastroenteritis causes 197,000 annual deaths, 23 children die due to this infection every hour. The high resistance of rotavirus in the environment, the ease of transmission and the large number of asymptomatic carriers predetermine the need for timely vaccination. There are 2 licensed oral live attenuated rotavirus vaccines on the international market, one of which is RotaTeq pentavalent vaccine.

show abstract

Cost-effectiveness of meningococcal vaccination of infants in the Russian Federation

Рудакова¹,

Вильниц²,

Харит³

et al. 2021

jour

View full text Add to dashboard Cite

Generalized forms of invasive meningococcal desease (IMD) are very dangerous because they have a high mortality rate.The aim of the work was to assess the cost-effectiveness of meningococcal vaccination of infants with the 4-valent MenACWY-D conjugate vaccine in the Russian Federation.Material and methods. Cost-effectiveness analysis based on epidemiological data for the Russian Federation was carried out by a modeling method with a horizon of 80 years from the position of the healthcare system and taking into account the social perspective. Vaccination costs were calculated on the basis of the registered price of the vaccine, including VAT, the costs of GFMI therapy and patient rehabilitation – based on the compulsory medical insurance tariffs in St. Petersburg for 2021. Indirect costs due to temporary disability of patients’ parents, disability of patients and premature death were estimated by the lost GDP. In the base case, costs were discounted by 3,5% per year, life expectancy – by 1,5% per year.Results. Given the assumptions made, the average lifetime burden of a child’s illness is 17,556 million rubles. (no discounting). In the base case, the incremental cost per LYG from the payer perspective – 7,821 million rubles, and from the social perspective – 3,328 million rubles. Incremental cost per QALY – 5,350 million rubles and 2,277 million rubles, respectively. The most important factors that have a significant impact on the cost-effectiveness of vaccination are the incidence of IMD, the price of the vaccine, and the value of the discounting of costs and life expectancy.Conclusions. Given the assumptions made, meningococcal vaccination of infants with 4-valent meningococcal vaccine can be considered as a viable option.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

334 Leonard St

Brooklyn, NY 11211

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Evaluation of the Cost-Effectiveness of Vaccination of Children with 5-valent Vaccine against Rotavirus Infection in the Russian Federation

Cited by 6 publications

References 35 publications

New Possibilities of Preventive Immunization for Rotavirus Infection in Russian Federation. Overview of the Innovative Rotavirus Vaccine Profile

New Possibilities of Preventive Immunization for Rotavirus Infection in Russian Federation. Overview of the Innovative Rotavirus Vaccine Profile

Rotavirus infection. the possibilities of timely vaccination

Cost-effectiveness of meningococcal vaccination of infants in the Russian Federation

Contact Info

Product

Resources

About